Agomab Therapeutics NV: Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn's Disease

-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming

Related Keywords

Eva Mulder ,Tim Knotnerus ,Philippe Wiesel ,Schwierige Zeiten ,Trophic Communications ,Fibrostenosing Crohn ,Chief Medical Officer ,Agomab Therapeutics ,Stephanie May ,Agomab ,Herapeutics ,Reports ,Positive ,Hase ,Results ,Gmb ,Estricted ,Dlk5 ,Inhibitor ,Ibrostenosing ,Brohn ,Disease ,